Cathepsin B Inhibition Limits Bone Metastasis in Breast Cancer
Authors:
- Galia BlumGBGalia Blum
- Mansoureh SameniMSMansoureh Sameni
- Clare SlaneyCSClare Slaney
- Arulselvi AnbalaganAAArulselvi Anbalagan
- Mary B. OliveMOMary B. Olive
- Bradley N. BidwellBBBradley N. Bidwell
- Laura EdgingtonLELaura Edgington
- Ling WangLWLing Wang
- Kamiar MoinKMKamiar Moin
- Bonnie F. SloaneBSBonnie F. Sloane
- Robin L. AndersonRARobin L. Anderson
Open Access
- 1 March 2012
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (5) , 1199-1209
Abstract
Metastasis to bone is a major cause of morbidity in breast cancer patients, emphasizing the importance of identifying molecular drivers of bone metastasis for new therapeutic targets. The endogenous cysteine cathepsin inhibitor stefin A is a suppressor of breast cancer metastasis to bone that is coexpressed with cathepsin B in bone metastases. In this study, we used the immunocompetent 4T1.2 model of breast cancer which exhibits spontaneous bone metastasis to evaluate the function and therapeutic targeting potential of cathepsin B in this setting of advanced disease. Cathepsin B abundancy in the model mimicked human disease, both at the level of primary tumors and matched spinal metastases. RNA interference–mediated knockdown of cathepsin B in tumor cells reduced collagen I degradation in vitro and bone metastasis in vivo. Similarly, intraperitoneal administration of the highly selective cathepsin B inhibitor CA-074 reduced metastasis in tumor-bearing animals, a reduction that was not reproduced by the broad spectrum cysteine cathepsin inhibitor JPM-OEt. Notably, metastasis suppression by CA-074 was maintained in a late treatment setting, pointing to a role in metastatic outgrowth. Together, our findings established a prometastatic role for cathepsin B in distant metastasis and illustrated the therapeutic benefits of its selective inhibition in vivo. Cancer Res; 72(5); 1199–209. ©2012 AACR.Keywords
All Related Versions
This publication has 50 references indexed in Scilit:
- Protective role of cathepsin L in mouse skin carcinogenesisMolecular Carcinogenesis, 2011
- Cathepsin B: a potential prognostic marker for inflammatory breast cancerJournal of Translational Medicine, 2011
- Bone Metastases: Molecular Mechanisms and Novel Therapeutic InterventionsMedicinal Research Reviews, 2010
- Cathepsin L, target in cancer treatment?Life Sciences, 2010
- Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo studyMolecular Cancer, 2010
- Cathepsin K inhibitors for osteoporosis and potential off-target effectsExpert Opinion on Investigational Drugs, 2009
- Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formationExperimental Cell Research, 2009
- Imaging and quantifying the dynamics of tumor-associated proteolysisClinical & Experimental Metastasis, 2008
- Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse modelBiological Chemistry, 2008
- Cathepsin G Enhances Mammary Tumor–Induced Osteolysis by Generating Soluble Receptor Activator of Nuclear Factor-κB LigandCancer Research, 2008